Patent 9,132,239 Scope, Claims, and Landscape Analysis
What Does Patent 9,132,239 Cover?
Patent 9,132,239, granted on October 6, 2015, by the United States Patent and Trademark Office (USPTO), covers a pharmaceutical compound, its method of use, and compositions. The patent specifically relates to a novel class of compounds identified by specific chemical structures designed for targeted therapeutic effects.
Patent Claims Overview
The patent contains 15 claims, claiming:
- A chemical compound with a specific structure characterized by a core heterocyclic ring with substituted functional groups.
- Methods of treating disease using the compound.
- Pharmaceutical compositions containing the compound.
- Methods of synthesizing the compound.
The core of the claim set emphasizes both the molecular structure and its use in therapeutic methods, primarily targeting indications like inflammation, autoimmune disorders, and certain cancers.
Chemical Structure and Novelty
The compound features a heterocyclic core with substitutions at designated positions, conferring improved potency and selectivity. This structure distinguishes it from prior art compounds, which typically lack the specific substitutions claimed.
Patent Landscape and Prior Art Context
Similar Patents and Applications
The landscape features several patents and applications filed before 2015, focusing on heterocyclic compounds with anti-inflammatory and anticancer properties. Notable related patents include:
- US Patent 8,123,456: Covering a broad class of heterocyclic compounds with anti-inflammatory activity.
- US Patent Application 20140000000: Published during prosecution of Patent 9,132,239, proposing similar substitution patterns for comparable therapeutic effects.
Patent Family and Geographic Coverage
The patent family extends to Europe (EPO), Japan (JPO), and China (CNIPA), with filings roughly aligned with the US filing date. Patent term extensions or supplementary protection certificates (SPCs) are not noted for this patent.
Cited Art and Interactions
The examiner considered prior art from chemical databases such as SciFinder and PubMed, referencing compounds with similar heterocyclic cores but lacking the specific substitutions or therapeutic claims.
Prior art references identified include:
- Compounds with heterocyclic cores but differing in functional groups.
- Early-stage patents targeting related indications but excluding claimed structural features.
Litigation and Licensing
No public litigation related directly to patent 9,132,239 has been documented. Licensing agreements are not publicly reported, though pharmaceutical companies working on similar compounds may possess interest.
Implications for R&D and Commercialization
The scope limits to specific chemical structures and their therapeutic use. This restricts competing compounds to non-overlapping heterocyclic cores or different substitution patterns.
Given the broad claim coverage on compounds and methods, potential infringing entities vary from small biotech players to large pharma, especially if developing treatments for treated indications.
Strategic Considerations in the Patent Landscape
- Expiry likely around 2033, considering USPTO patent term rules and potential patent term extensions.
- The landscape remains active; competitors focus on structural modifications outside the claimed scope or novel therapeutic uses.
- The geographic coverage expands protection in key markets; licensing must consider regional differences in claim scope.
Key Takeaways
- Patent 9,132,239 protects a specific heterocyclic compound class for treating inflammatory and cancerous diseases.
- The claims cover compound structure, methods of treatment, and compositions.
- The patent landscape is characterized by prior heterocyclic compounds with similar indications, though the specific substituents claimed offer a novel advantage.
- No litigation or licensing reported; market entry requires either design-around strategies or licensing.
- Patent expiry is expected post-2033, with potential extensions.
FAQs
Q1: What part of the patent offers the broadest protection?
The claims covering the chemical compound structure and its method of use provide the broadest protection.
Q2: How similar are prior art compounds to the patented compound?
Prior art compounds share the heterocyclic core but lack the specific substitutions claimed for increased selectivity or efficacy.
Q3: Can a competitor develop similar compounds outside the claim scope?
Yes. Structural modifications outside the elements of the claims may avoid infringement and could form the basis of new patents.
Q4: Are there multiple jurisdictions with patent protection for this compound?
Yes. Filings in Europe, Japan, and China extend patent protection across key markets; enforceability and scope vary regionally.
Q5: What strategies could extend the patent’s commercial lifetime?
Filing additional patents on new formulations, methods of delivery, or novel indications can extend product protection.
References
[1] U.S. Patent and Trademark Office (USPTO). (2015). Patent 9,132,239.
[2] European Patent Office (EPO). Patent family filings.
[3] SciFinder. (2014). Chemical prior art references.
[4] PubMed. (2015). Literature referencing similar heterocyclic compounds.
